At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,121 enrolled
Drug / intervention
ALD403 (Eptinezumab) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
In Brief
A Phase 3 clinical trial evaluating ALD403 (Eptinezumab) and Placebo for Migraine Disorders. Completed, enrolled 1,121 participants across 144 sites in 13 countries.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesBelgium, Czechia, Denmark, Georgia, Germany, Hungary, Italy, Russia, Slovakia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedNov 2016
Primary CompletionNov 2017
Study CompletionApr 2018
TodayJul 2026
First PostedNov 28, 2016
Enrollment StartNov 1, 2016
Primary CompletionNov 1, 2017
Study CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 9.6 years ago
Interventions
ALD403 (Eptinezumab)biological
Placebobiological